| scholarly article | Q13442814 |
| P356 | DOI | 10.1039/C4OB00364K |
| P698 | PubMed publication ID | 24781551 |
| P2093 | author name string | Sheng Liu | |
| Fajun Nan | |||
| Jing Ai | |||
| Xia Peng | |||
| Meiyu Geng | |||
| Jimin Xu | |||
| Linqian Yu | |||
| P2860 | cites work | Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 |
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival | Q28282398 | ||
| Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors | Q28295039 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| Biomimetically inspired total synthesis and structure activity relationships of 1-O-methyllateriflorone. 6 pi electrocyclizations in organic synthesis | Q31053049 | ||
| Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis | Q33786959 | ||
| Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates | Q34088416 | ||
| Small molecule c-Met kinase inhibitors: a review of recent patents | Q34094632 | ||
| Development of c-MET pathway inhibitors | Q34198905 | ||
| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
| Drug development of MET inhibitors: targeting oncogene addiction and expedience | Q34782774 | ||
| Mechanisms and significance of bifunctional NK4 in cancer treatment. | Q36160343 | ||
| Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo | Q37133949 | ||
| Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. | Q37223558 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| Targeting the heat shock protein 90 dimer with dimeric inhibitors | Q38604353 | ||
| Enantioselective total syntheses of trichodermamides A and B. | Q39922084 | ||
| Expeditious synthesis of benzopyrans via Lewis acid-catalyzed C-H functionalization: remarkable enhancement of reactivity by an ortho substituent | Q43123804 | ||
| Biscoumarin: new class of urease inhibitors; economical synthesis and activity. | Q44401752 | ||
| C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu | Q45083973 | ||
| Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists. | Q51759767 | ||
| Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma | Q57765077 | ||
| P433 | issue | 22 | |
| P304 | page(s) | 3721-3734 | |
| P577 | publication date | 2014-04-30 | |
| P1433 | published in | Organic and Biomolecular Chemistry | Q3355939 |
| P1476 | title | Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors | |
| P478 | volume | 12 |
| Q50245721 | Total syntheses of gerberinol I and the pterophyllins 2 and 4 using the Casnati-Skattebøl reaction under different conditions | cites work | P2860 |
Search more.